Is that good, or are we just throwing money into more research that is being outdone by our competitors already? What's the point?
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-5
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.50 |
Change
0.210(0.99%) |
Mkt cap ! $413.0M | |||
| Open | High | Low | Value | Volume |
| $21.50 | $21.50 | $21.00 | $247.6K | 11.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $21.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.50 | 244 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.21 |
Change
0.210 ( 0.09 %) |
||||
| Open | High | Low | Volume | ||
| $21.19 | $21.21 | $21.19 | 143 | ||
| Last updated 14.24pm 06/05/2024 ? | |||||
| AVR (ASX) Chart |